Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study ShowsBenzinga • 05/12/21
INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical StudiesPRNewsWire • 05/12/21
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Inovio's stock is up after it shares new data from Phase 2 clinical trial for its COVID-19 vaccine candidateMarket Watch • 05/10/21
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA VaccinePRNewsWire • 05/10/21
Is Inovio Stock A Sell After U.S. Officials Cut Funding For Covid Vaccine?Investors Business Daily • 04/29/21
Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trialBusiness Insider • 04/23/21
Inovio Stock Collapses After U.S. Officials Pull Funding For Covid Vaccine TestInvestors Business Daily • 04/23/21
Inovio stock plunges after U.S. government stops funding of Phase 3 trial of COVID-19 vaccine candidateMarket Watch • 04/23/21
Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global TrialBenzinga • 04/23/21